Isofol is attending the ESMO 2018 Congress in Germany, which is taking place between October 19-23. During Sunday the poster, “ISO-CC-005; a phase I/II study of arfolitixorin ([6R]-5,10-MTHF) in combination with 5-fluorouracil (5-FU), irinotecan and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer”, will be presented.
The poster is visible from October 21 at 9 am in hall A3 and has the poster no 569P.
